XML 62 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation (Narrative) (Details) (USD $)
 3 Months Ended 6 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2014
storage_location
drug
Jun. 30, 2013
Jun. 30, 2014
segment
storage_location
drug
Jun. 30, 2013
Dec. 31, 2013
Jun. 30, 2014
Equipment
Minimum
Jun. 30, 2014
Equipment
Maximum
Apr. 30, 2013
Royalty Stream and Milestone Payments Purchase Agreement with Selexis
program
Jun. 30, 2014
Cydex Pharmaceuticals, Inc
Jun. 30, 2013
Cydex Pharmaceuticals, Inc
Jun. 30, 2014
Cydex Pharmaceuticals, Inc
Jun. 30, 2013
Cydex Pharmaceuticals, Inc
Dec. 31, 2013
Cydex Pharmaceuticals, Inc
Jan. 31, 2011
Cydex Pharmaceuticals, Inc
Jan. 31, 2012
Cydex Pharmaceuticals, Inc
Guaranteed Payment
Jun. 30, 2014
Cydex Pharmaceuticals, Inc
Revenue Sharing
Jun. 30, 2013
Cydex Pharmaceuticals, Inc
Revenue Sharing
Jun. 30, 2013
Cydex Pharmaceuticals, Inc
Revenue Sharing
Jan. 31, 2010
Metabasis Therapeutics
right
Jun. 30, 2014
Metabasis Therapeutics
Jun. 30, 2013
Metabasis Therapeutics
Jun. 30, 2014
Metabasis Therapeutics
Jun. 30, 2013
Metabasis Therapeutics
Dec. 31, 2013
Metabasis Therapeutics
Jun. 30, 2014
Accounts Receivable
Customer Concentration Risk
customer
Dec. 31, 2013
Accounts Receivable
Customer Concentration Risk
customer
Jun. 30, 2014
Acquired In Process Research And Development
Jun. 30, 2014
Acquired In Process Research And Development
Jun. 30, 2014
Omthera Pharmaceuticals
Jun. 30, 2014
Viking
Property, Plant and Equipment [Line Items]                                                            
Accumulated deficit $ 667,650,000   $ 667,650,000   $ 671,339,000                                                  
Working capital 10,000,000   10,000,000                                                      
Period for which available resources are sufficient to satisfy company's anticipated operating and capital requirements     12 months                                                      
Earnings (Loss) Per Share                                                            
Common shares excluded from computation     400,000 1,100,000                                                    
Cash, Cash Equivalents and Short-term Investments                                                            
Maturity period of cash and cash equivalents, maximum     3 months                                                      
Maturity period of short term investments, minimum     3 months                                                      
Concentrations of Credit Risk                                                            
FDIC insured amount 250,000   250,000                                                      
Cash deposits 13,900,000   13,900,000   11,100,000                                                  
Concentration risk, number of customers                                                 1 2        
Concentration risk, percentage of accounts receivable                                                 92.00% 75.00%        
Product Shelf Life     5 years                                                      
Number of Storage Locations 3   3                                                      
Property and Equipment                                                            
Estimated useful life of assets           3 years 10 years                                              
Depreciation 100,000 100,000 100,000 200,000                                                    
Goodwill and Other Identifiable Intangible Assets                                                            
Finite-lived intangible asset, useful life     20 years                                                      
Amortization expense 600,000   1,200,000                                                      
Amortization Expense                                                            
Amortization expense 2014 2,400,000   2,400,000                                                      
Amortization expense 2015 2,400,000   2,400,000                                                      
Amortization expense 2016 2,400,000   2,400,000                                                      
Amortization expense 2017 2,400,000   2,400,000                                                      
Amortization expense 2018 2,400,000   2,400,000                                                      
Acquired In-Process Research and Development                                                            
Impairment of in-process research and development 0 480,000 0 480,000                                             0 0    
Gain on write-off of assets     (16,000) 0           500,000   500,000                                    
Commercial License Rights                                                            
Number of commercial license agreement programs               15                                            
Purchase price               4,600,000                                            
Payments to acquire intangible assets               3,600,000                                            
Cash payment due on first anniversary of the closing               1,000,000                                            
Contingent Liabilities                                                            
Contingent liability                           17,600,000                                
Purchase of commercial license rights                             4,300,000 0 0 0                        
Fair value of liability                 10,400,000   10,400,000   9,300,000             4,700,000   4,700,000   4,200,000            
Contingent liability change in amount                 (3,200,000) (5,200,000) (2,700,000) (3,300,000)               (1,900,000) 2,500,000 500,000 2,400,000              
Number of contingent value rights                                     4                      
Number of contingent value rights per series of contingent value rights                                     1                      
Number of contingent value rights issued for each share                                     4                      
Contingent value rights, frequency of cash payment                                     6 months                      
Revenue Recognition                                                            
Period allowed for return of products, minimum     30 days                                                      
Period allowed for return of products, maximum     90 days                                                      
Treasury stock, shares         1,118,222                                                  
Allowance for Doubtful Accounts                                                            
Accounts receivable outstanding considered past due after period, minimum     30 days                                                      
Accounts receivable outstanding considered past due after period, maximum     90 days                                                      
Allowance for doubtful accounts 0   0   0                                                  
Sale of Royalty Rights                                                            
Deferred revenue 0   0   100,000                                                  
Milestone Payments                                                            
Event-based payment                                                         1,000,000  
Discontinued Operations                                                            
Number of drugs included in product line 4   4                                                      
Gain on sale of Avinza Product Line before income taxes 0 2,397,000 0 2,588,000                                                    
Segment Reporting                                                            
Number of reportable segments     2                                                      
Assets 99,847,000   99,847,000   104,713,000                                                 2,014,000
Liabilities $ 36,761,000   $ 36,761,000   $ 55,100,000                                                 $ 3,098,000